Research Article
Prognosis and Prognostic Factors of Serous Borderline Tumor-Micropapillary Variant: Retrospective Study of 200 Patients with Long-Term Follow-Up
Table 4
Prognostic factors for overall survival in women with SBOT-Ms (
).
| | Variables | Overall survival (OS) | | Univariate analysis | | N. DOD/total (%) | 5-year OS (%) | value |
| | Age (years) | ≤ 35 | 4/125 (3.2) | 97 | .383 | | >35 | 3/75 (4.0) | 97 | | | Nulliparous | No | 3/92 (3.3) | 98 | .786 | | Yes | 4/108 (3.7) | 96 | | | Surgical approach | Laparotomy | 5/134 (3.7) | 97 | .920 | | Laparoscopy | 2/66 (3.0) | 97 | | | Staging surgery | Yes | 5/127 (3.9) | 97 | .628 | | No | 2/73 (2.7) | 98 | | | Lymphadenectomy | Yes | 3/60 (5.0) | 96 | .460 | | No | 4/140 (2.9) | 97 | | | Surgical extent | Radical | 3/78 (3.8) | 97 | .542 | | Conservative | 4/122 (3.3) | 97 | | | Ovarian involvement | Unilateral | 1/63 (1.6) | 96 | .257 | | Bilateral | 6/137 (4.4) | 97 | | | FIGO stage† | I | 1/106 (0.9) | 96 | .017 | | II-IV | 6/94 (6.4) | 97 | | | Stromal microinvasion | No | 5/164 (3.0) | 98 | .355 | | Yes | 2/36 (5.6) | 97 | | | Type of implants () | Noninvasive | 4/68 (5.9) | 97 | .867 | | Invasive | 2/26 (7.7) | 90 | | | Chemotherapy | No | 4/146 (2.7) | 98 | .389 | | Yes | 3/54 (5.6) | 96 | |
|
|
†FIGO, International Federation of Gynecology and Obstetrics.
|
